Marker Therapeutics to Present MT-601 Data at ASH Annual Meeting

Marker Therapeutics announced upcoming presentations on MT-601 at the 67th ASH Annual Meeting, highlighting encouraging preliminary efficacy data from the Phase 1 APOLLO study. MT-601 demonstrated a robust safety profile with no dose-limiting toxicities or ICANS in the dose escalation cohort. The ongoing study investigates MT-601 in patients with relapsed B cell lymphomas, including those who relapsed after CAR-T cell therapy.